Bicycle Therapeutics plc (NasdaqGS: BCYC)
Health Care · Biotechnology · GB
$3.81
-2.06% today · -56.1% 1Y
Bicycle Therapeutics plc (NasdaqGS: BCYC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $272.27M and employs 288 people.
Over the last twelve months the share price has lost 56.1%, trading between 3.33 and 9.16.
Tweenvest scores Bicycle Therapeutics plc across four factors: quality 38/100, value 49/100, growth 100/100. Its strongest factor is growth.
BCYC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $272.27M
- Revenue (TTM)
- $61.20M
- P/E
- —
- EPS
- -2.74
- Dividend yield
- —
- Beta (5Y)
- 1.68
- 52-week high
- $9.16
- 52-week low
- $3.33
- Avg volume (3M)
- —
- Shares outstanding
- 69.99M
- Employees
- 288
- Next earnings
- —
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.
- ISIN
- US0887861088
- Founded
- 2009
- Listed since
- May 23, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AIM Vaccine Co., Ltd.SEHK: 6660 | $280.55M | HK$1.80 | +6.85% |
| Clinuvel Pharmaceuticals LimitedASX: CUV | $279.41M | AU$7.94 | +0.13% |
| Larimar Therapeutics, Inc.NasdaqGM: LRMR | $278.70M | $2.53 | -5.24% |
| Vanda Pharmaceuticals Inc.NasdaqGM: VNDA | $276.31M | $4.54 | -0.66% |
| SAB Biotherapeutics, Inc.NasdaqCM: SABS | $271.14M | $2.83 | -5.20% |
| Palisade Bio, Inc.NasdaqCM: PALI | $268.38M | $1.58 | +2.60% |
| Northwest Biotherapeutics, Inc.OTCPK: NWBO | $267.79M | $0.16 | +2.15% |
| Century Therapeutics, Inc.NasdaqCM: IPSC | $266.18M | $1.45 | -1.70% |
Figures last refreshed Oct 11, 2026.